JP2024531799A5 - - Google Patents
Info
- Publication number
- JP2024531799A5 JP2024531799A5 JP2024517163A JP2024517163A JP2024531799A5 JP 2024531799 A5 JP2024531799 A5 JP 2024531799A5 JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024531799 A5 JP2024531799 A5 JP 2024531799A5
- Authority
- JP
- Japan
- Prior art keywords
- months
- decitabine
- effective amount
- sedazulidine
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246547P | 2021-09-21 | 2021-09-21 | |
| US63/246,547 | 2021-09-21 | ||
| PCT/US2022/076757 WO2023049731A2 (en) | 2021-09-21 | 2022-09-21 | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531799A JP2024531799A (ja) | 2024-08-29 |
| JP2024531799A5 true JP2024531799A5 (https=) | 2025-09-30 |
Family
ID=85721229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517163A Pending JP2024531799A (ja) | 2021-09-21 | 2022-09-21 | 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250000888A1 (https=) |
| EP (1) | EP4404940A4 (https=) |
| JP (1) | JP2024531799A (https=) |
| KR (1) | KR20240064656A (https=) |
| CN (1) | CN118201622A (https=) |
| AU (1) | AU2022348907A1 (https=) |
| CA (1) | CA3232623A1 (https=) |
| MX (1) | MX2024003537A (https=) |
| TW (1) | TW202327625A (https=) |
| WO (1) | WO2023049731A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024229073A1 (en) * | 2023-05-02 | 2024-11-07 | Otsuka Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2249831A2 (en) * | 2007-12-10 | 2010-11-17 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| WO2016085876A1 (en) * | 2014-11-25 | 2016-06-02 | The Broad Institute Inc. | Clonal haematopoiesis |
| US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| WO2021113688A1 (en) * | 2019-12-05 | 2021-06-10 | Sumitomo Dainippon Pharma Oncology, Inc. | Combination therapies for treatment of myelodysplastic syndrome |
| BR112022012310A2 (pt) * | 2020-01-17 | 2022-09-06 | Novartis Ag | Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica |
| US12239653B2 (en) * | 2020-02-25 | 2025-03-04 | Taiho Pharmaceutical Co., Ltd. | Combination decitabine and cedazuridine solid oral dosage forms |
-
2022
- 2022-09-21 KR KR1020247010215A patent/KR20240064656A/ko active Pending
- 2022-09-21 MX MX2024003537A patent/MX2024003537A/es unknown
- 2022-09-21 TW TW111135794A patent/TW202327625A/zh unknown
- 2022-09-21 US US18/693,727 patent/US20250000888A1/en active Pending
- 2022-09-21 CN CN202280073476.0A patent/CN118201622A/zh active Pending
- 2022-09-21 JP JP2024517163A patent/JP2024531799A/ja active Pending
- 2022-09-21 WO PCT/US2022/076757 patent/WO2023049731A2/en not_active Ceased
- 2022-09-21 AU AU2022348907A patent/AU2022348907A1/en active Pending
- 2022-09-21 CA CA3232623A patent/CA3232623A1/en active Pending
- 2022-09-21 EP EP22873816.7A patent/EP4404940A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022180461A5 (https=) | ||
| JP2023041862A5 (https=) | ||
| JP2024015120A5 (https=) | ||
| JP2012521435A5 (https=) | ||
| JP2021527092A5 (https=) | ||
| JP2022537551A5 (https=) | ||
| JP2023541430A5 (https=) | ||
| JP2014515373A5 (https=) | ||
| JP2022521233A5 (https=) | ||
| JP2021509395A5 (https=) | ||
| JP2024016209A5 (https=) | ||
| JP2025148449A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JP2022553888A5 (https=) | ||
| JP2024531799A5 (https=) | ||
| JP2024540439A5 (https=) | ||
| TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
| JP2024528731A5 (https=) | ||
| JP2021517128A5 (https=) | ||
| JP2025504984A5 (https=) | ||
| JP2024520690A5 (https=) | ||
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| JP2023517130A5 (ja) | Ａｚｄ１６５６又はその薬学的に許容される塩を含む、コロナウイルスによって引き起こされた肺炎及び／又は心筋炎の治療用組成物 | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| JP2025511402A5 (https=) |